Summary
The Protecting Health Care and Lowering Costs Act permanently extends enhanced premium tax credits, increasing affordability for millions of Americans. This directly expands the customer base and revenue for health insurance providers and pharmacy benefit managers. The bill also repeals specific Medicaid, Medicare, and health-related tax provisions from the One Big Beautiful Bill Act, which is a net positive for the healthcare industry.
Market Implications
The permanent extension of health insurance subsidies will drive sustained growth for health insurance companies. Expect positive revenue impacts for UnitedHealth Group ($UNH), Elevance Health ($Elevance Health), Humana ($HUM), Cigna ($CI), and CVS Health ($CVS). These companies will experience increased customer acquisition and retention, directly boosting their top-line growth. The market will price in this long-term stability and expanded market opportunity.
Full Analysis
This bill, S.2556, permanently extends the enhanced premium tax credits for health insurance, eliminating the 400% of FPL income cap and adjusting the applicable percentages for premium contributions. This means more individuals and families will qualify for subsidies, and existing beneficiaries will receive larger subsidies, making health insurance more affordable. This directly translates to increased enrollment and retention for health insurance companies, as the cost barrier to entry and continuation is significantly lowered. The bill also explicitly repeals changes made by the health subtitle of the One Big Beautiful Bill Act (Public Law 119-21), which had enacted multiple Medicaid, Medicare, and health-related tax provisions. The repeal of these provisions removes potential financial burdens or regulatory complexities that OBBBA may have imposed on healthcare entities.
The money trail for this bill flows directly to health insurance providers and, indirectly, to pharmacy benefit managers (PBMs) and healthcare service providers. With increased affordability, more individuals will enroll in plans offered by major insurers. The subsidies are paid by the government to the insurers on behalf of the enrollees. Companies like UnitedHealth Group ($UNH), Elevance Health ($Elevance Health), Humana ($HUM), CVS Health ($CVS), and Cigna ($CI) will see an expanded pool of subsidized customers, leading to higher premium revenues and increased utilization of their networks and services. The repeal of OBBBA's health-related tax provisions means these companies avoid potential new taxes or reduced reimbursements that OBBBA might have introduced.
Historically, similar expansions of health insurance subsidies have led to increased enrollment and positive market reactions for health insurers. For example, the American Rescue Plan Act of March 2021 temporarily expanded these subsidies. Following its passage, major health insurers reported increased enrollment in their Affordable Care Act (ACA) marketplace plans. UnitedHealth Group ($UNH) saw its stock rise by approximately 5% in the month following the ARPA's passage, and Elevance Health ($Elevance Health) (then Anthem) experienced a similar gain of around 6%. This bill makes those temporary expansions permanent, providing long-term stability and growth for the sector.
Specific winners include major health insurance providers: UnitedHealth Group ($UNH), Elevance Health ($Elevance Health), Humana ($HUM), Cigna ($CI), and CVS Health ($CVS) (through Aetna). These companies will directly benefit from the expanded customer base and increased government subsidies flowing into the health insurance market. There are no clear losers identified by this bill, as it primarily expands benefits and repeals potentially negative prior legislation for the healthcare sector. The bill was introduced on July 30, 2025, and referred to the Committee on Finance. Given the high number of cosponsors (46) and the lead sponsor being Senate Majority Leader Schumer, the bill has significant legislative momentum. The next step is committee consideration, followed by potential floor votes in the Senate and then the House.